Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
Sign Up to like & getrecommendations! Published in 2020 at "Hepatology"
DOI: 10.1002/hep.31268
Abstract: We thank Drs. Chen and Vitetta for their letter regarding our manuscript describing our phase 2 study of the nonsteroidal farnesoid X receptor (FXR) agonist cilofexor in non-cirrhotic patients with primary sclerosing cholangitis (PSC).1 As… read more here.
Keywords: letter; primary sclerosing; sclerosing cholangitis; agonist cilofexor ... See more keywords